Catalent Launches New OptiDose Design Solution

Catalent has launched its new OptiDose Design Solution, an approach that combines data-driven scientific tools with Catalent’s development expertise led by its scientific advisors. Integrating pharmaceutics, and dose form design target patient characteristics, OptiDose Design Solution aims to help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.

“Taking patient needs and market realities into consideration earlier in the drug development process, along with critical CMC and DMPK parameters, is vital for creating a successful treatment for patients, innovators and health care professionals alike,” said Julien Meissonnier, Chief Scientific Officer at Catalent. “The OptiDose Design platform looks to evaluate all these considerations and provide options for final dose form decisions with an optimal combination of patient acceptance and adherence, differentiation versus any standard of care, manufacturability and cost.”

Catalend launched the new OptiDose Design Solution at the virtual Controlled Release Society (CRS) annual meeting taking place July 25 – 29, 2021.

At the CRS meeting, Lisa Caralli, Director of Science and Technology at Catalent, discusses the methodology of the OptiDose Design Solution, including how key product and patient factors are evaluated. Ms. Caralli’s presentation, titled “Strategies to Optimize the Dose Design Process to Create Better Treatments”, uses case studies to demonstrate how the correct guidance, at the optimum time, can help drug developers create better treatments.

Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with bio pharmaceuticals companies to identify appropriate development pathways for early development drug candidates.

OptiDose Design Solution is available throughout Catalent’s global oral dose network.